Using a multicellular lung-on-a-chip model, co-culturing human NSCLC cell line HCC827, human fetal lung fibroblasts HFL-1, and human umbilical vein endothelial cells HUVECs, researchers demonstrated that IL-6-mediated fibroblast activation and EMT contribute to osimertinib resistance, which can be partially reversed by IL-6 inhibition with tocilizumab. Here, IL6 is linked to non-small cell lung carcinoma.